Macrolide resistance in the normal microbiota after Helicobacter pylori treatment

Scandinavian Journal of Infectious Diseases

Volumn 39, Issue 9, 2007, Pages 757-763

  Jakobsson, Hedvig ^a,b   Wreiber, Karin ^a   Fall, Katja ^b   Fjelstad, Björn ^c   Nyrén, Olof ^b   Engstrand, Lars ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MORA HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MACROLIDE; METRONIDAZOLE; OMEPRAZOLE;

ADULT; AGED; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTEROIDES; CONTROLLED STUDY; DYSPEPSIA; ENTEROCOCCUS; ERADICATION THERAPY; FEMALE; GASTROSCOPY; HEALTH PROGRAM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; PEPTIC ULCER; PREVALENCE; STAPHYLOCOCCUS; STREPTOCOCCUS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEROIDES; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FECES; FEMALE; GRAM-POSITIVE COCCI; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NOSE; OMEPRAZOLE; PHARYNX; PROSPECTIVE STUDIES;

EID: 34548136645     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701299608     Document Type: Article

References (28)

1. Kuipers, EJ, Thijs, JC and Festen, HP. (1995) The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther, 9, pp. 59-69.
2. Pounder, RE and Ng, D. (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther, 9, pp. 33-39.
3. The European Helicobacter pylori Study Group
4. Parsonnet, J., Harris, RA H., Hack, M. and Owens, DK. (1996) Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials. Lancet, 348, pp. 150-154.
5. Bergman, M., Huikko, S., Pihlajamaki, M., Laippala, P., Palva, E. and Huovinen, P. (2004) Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis, 38, pp. 1251-1256.
6. Seppala, H., Klaukka, T., Lehtonen, R., Nenonen, E. and Huovinen, P. (1995) Outpatient use of erythromycin: Link to increased erythromycin resistance in group A streptococci. Clin Infect Dis, 21, pp. 1378-1385.
7. Seppala, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H. and Lager, K. (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med, 337, pp. 441-446.
8. Rahal, JJ, Urban, C., Horn, D., Freeman, K., Segal-Maurer, S. and Maurer, J. (1998) Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA, 280, pp. 1233-1237.
9. Megraud, F. (2004) H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut, 53, pp. 1374-1384.
10. Eady, EA, Coates, P., Ross, JI, Ratyal, AH and Cove, JH. (2000) Antibiotic resistance patterns of aerobic coryneforms and furazolidone-resistant Gram-positive cocci from the skin surface of the human axilla and fourth toe cleft. J Antimicrob Chemother, 46, pp. 205-213.
11. Kataja, J., Huovinen, P., Skurnik, M. and Seppala, H. (1999) Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Chemother, 43, pp. 48-52.
12. Bryskier, A. (2002) Viridans group streptococci: A reservoir of resistant bacteria in oral cavities. Clin Microbiol Infect, 8, pp. 65-69.
13. Luna, VA, Coates, P., Eady, EA, Cove, JH, Nguyen, TT and Roberts, MC. (1999) A variety of Gram-positive bacteria carry mobile mef genes. J Antimicrob Chemother, 44, pp. 19-25.
14. Fille, M., Mango, M., Lechner, M. and Schaumann, R. (2006) Bacteroides fragilis group: Trends in resistance. Curr Microbiol, 52, pp. 153-157.
15. The Swedish Reference Group for Antibiotics
16. Adamsson, I., Nord, CE, Lundquist, P., Sjostedt, S. and Edlund, C. (1999) Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother, 44, pp. 629-640.
17. Buhling, A., Radun, D., Muller, WA and Malfertheiner, P. (2001) Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther, 15, pp. 1445-1452.
18. Stark, CA, Adamsson, I., Edlund, C., Sjosted, S., Seensalu, R. and Wikstrom, B. (1996) Effects of omeprazole and amoxycillin on the human oral and gastrointestinal microflora in patients with Helicobacter pylori infection. J Antimicrob Chemother, 38, pp. 927-939.
19. Matute, AJ, Schurink, CA, Krijnen, RM, Florijn, A. M., Rozenberg-Arska, M. and Hoepelman, IM. (2002) Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers. Eur J Clin Microbiol Infect Dis, 21, pp. 427-431.
20. Sjolund, M., Wreiber, K., Andersson, DI, Blaser, MJ and Engstrand, L. (2003) Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med, 139, pp. 483-487.
21. Lofmark, S., Jernberg, C., Jansson, JK and Edlund, C. (2006) Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother, 58, pp. 1160-1167.
22. Bjorkman, J., Hughes, D. and Andersson, DI. (1988) Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci U S A, 95, pp. 3949-3953.
23. Hunt, RH and Huang, JQ. (1998) The case for treatment of dyspeptic patients infected with H. pylori. Eur J Surg Suppl, pp. 6-10.
24. McCarthy, DM. (1998) H. pylori infection in non-ulcer patients: To treat or not to treat. The case against treatment. Eur J Surg Suppl, pp. 11-15.
25. McColl, K., Murray, L., El-Omar, E., Dickson, A., El-Nujumi, A. and Wirz, A. (1998) Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med, 339, pp. 1869-1874.
26. Moayyedi, P., Feltbower, R., Brown, J., Mason, S., Mason, J. and Nathan, J. (2000) Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: A randomized controlled trial. Leeds HELP Study Group. Lancet, 355, pp. 1665-1669.
27. Moayyedi, P., Soo, S., Deeks, J., Delaney, B., Harris, A. and Innes, M. (2006) Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev:CD002096
28. Moayyedi, P., Soo, S., Deeks, J., Forman, D., Mason, J. and Innes, M. (2000) Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. Br Med J, 321, pp. 659-664.